Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Insulet Corporation - Common Stock
(NQ:
PODD
)
244.67
-3.71 (-1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Insulet Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Expert Ratings For Insulet
December 21, 2023
Via
Benzinga
Should you consider NASDAQ:PODD for growth investing?
December 19, 2023
Exploring growth characteristics of INSULET CORP (NASDAQ:PODD).
Via
Chartmill
What 8 Analyst Ratings Have To Say About Insulet
December 04, 2023
Via
Benzinga
Should you consider NASDAQ:PODD for growth investing?
November 28, 2023
Why INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock.
Via
Chartmill
Insulet to Present at Upcoming Investor Conferences
November 28, 2023
From
Insulet Corporation
Via
Business Wire
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
November 17, 2023
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
10 Health Care Stocks Whale Activity In Today's Session
November 15, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 10, 2023
Via
Benzinga
Wall Street sees these 2023 losers as 2024 opportunities
November 09, 2023
Analysts are pointing at undervalued, oversold companies like these three S&P 500 laggards as potential investment opportunities heading into 2024.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
What Stocks Drove The Recent Record Rally? A Breakdown You Can't Miss
November 07, 2023
The technology sector has done well during the recent stock market rally as seen in indices such as Nasdaq 100 and S&P 500.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why the growth investor may take a look at NASDAQ:PODD.
November 07, 2023
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Expert Ratings for Insulet
October 16, 2023
Via
Benzinga
Large cap earnings trade ideas for risk-seeking investors
November 07, 2023
Positive earnings surprises (and the magnitude of surprises) are above historical norms as of late - and these three stocks could keep the party going.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
November 04, 2023
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.
Via
Benzinga
Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations
November 03, 2023
Insulet makes an insulin pump called Omnipod. U.S. sales are on the rise.
Via
Investor's Business Daily
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Shares of Insulet Dropped This Week
October 12, 2023
Positive news regarding diabetes therapy Ozempic worried investors.
Via
The Motley Fool
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
November 03, 2023
Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the
Via
Benzinga
Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1)
November 02, 2023
From
Insulet Corporation
Via
Business Wire
Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November
November 01, 2023
From
Insulet Corporation
Via
Business Wire
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
October 27, 2023
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story.
Via
Investor's Business Daily
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone
October 23, 2023
From
Insulet Corporation
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Why Insulet Stock Traded Lower
October 05, 2023
Insulet Corporation (NASDAQ: PODD) shares traded lower Thursday.
Via
Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
October 04, 2023
Benzinga
Via
Benzinga
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
October 04, 2023
More than 70% of S&P 500 stocks finished in the red last quarter, but the broad-based selloff may be an opportunity - including for these three biggest losers.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Stocks
Exposures
Artificial Intelligence
Interest Rates
US Equities
Tubeless Insulin Pump Technology Provider Insulet's CFO Resigns; Reaffirms Q3, FY23 Outlook
October 04, 2023
Medical device company Insulet Corp (NASDAQ: PODD) disclosed that Wayde McMillan has decided to resign as Executive Vice President,
Via
Benzinga
Insulet Announces CFO Transition
October 03, 2023
From
Insulet Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
October 02, 2023
Via
Benzinga
FedEx To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Monday
October 02, 2023
JP Morgan raised the price target for The Progressive Corporation (NYSE: PGR) from $146 to $149. JP Morgan analyst Jimmy Bhullar maintained an Overweight rating. Progressive shares fell 0.8% to close...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.